PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

calcium carbonate Side Effects

The reactions most often reported to the FDA for calcium carbonate (also sold as Tums, Caltrate), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

64,404
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2002 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of calcium carbonate come from 64,404 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 64,404 reports to the FDA Adverse Event Reporting System (FAERS) for calcium carbonate (Tums): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

64,404

Reports Mentioning Death

8,716

13.5% of reports — not proof the medicine caused the death

Hospitalizations

27,035

42.0% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

FATIGUE
6,169
NAUSEA
5,635
DIARRHOEA
4,987
CHRONIC KIDNEY DISEASE
4,954
PAIN
4,920
DYSPNOEA
4,648
VOMITING
4,414
HEADACHE
4,195
PNEUMONIA
3,743
ACUTE KIDNEY INJURY
3,708
ARTHRALGIA
3,708
MALAISE
3,588
PYREXIA
3,406
DIZZINESS
3,245
ASTHENIA
3,239
RASH
3,211
RENAL FAILURE
3,160
CONDITION AGGRAVATED
3,107

Who Reports Side Effects

Gender Distribution

Female 39,878 (67%)
Male 19,397 (33%)
Unknown 63

Age Distribution

0-17 1,542 (4%)
18-44 7,018 (17%)
45-64 13,889 (33%)
65-74 10,128 (24%)
75+ 9,334 (22%)

Reporting Trend by Year

2002 2025

Reactions in Death Reports

Top reactions reported in 8,716 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 2,195
FATIGUE 1,498
HYPERTENSION 1,443
GENERAL PHYSICAL HEALTH DETERIORATION 1,430
TYPE 2 DIABETES MELLITUS 1,341
RHEUMATOID ARTHRITIS 1,338
SYSTEMIC LUPUS ERYTHEMATOSUS 1,335
VOMITING 1,322
HYPOAESTHESIA 1,309
INFUSION RELATED REACTION 1,298
DYSPNOEA 1,292
GLOSSODYNIA 1,277
SWELLING 1,277
PSORIATIC ARTHROPATHY 1,267
RASH 1,266
HAND DEFORMITY 1,256
HEPATIC ENZYME INCREASED 1,255
CONDITION AGGRAVATED 1,244
PAIN 1,241

Reactions in Hospitalization Reports

Top reactions in 27,035 reports where hospitalization was an outcome.

Reaction Reports
NAUSEA 3,166
FATIGUE 3,019
VOMITING 2,934
DYSPNOEA 2,836
PNEUMONIA 2,805
DIARRHOEA 2,743
PAIN 2,654
PYREXIA 2,508
MALAISE 2,341
HEADACHE 2,288
ASTHENIA 2,252
CONDITION AGGRAVATED 2,045
ARTHRALGIA 2,028
HYPERTENSION 2,028
FALL 1,963
CONFUSIONAL STATE 1,924
DIZZINESS 1,811
RHEUMATOID ARTHRITIS 1,750

Compare calcium carbonate vs ascorbic acid →

What the FAERS Data Reveals About calcium carbonate Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 64,404 voluntary reports linked to calcium carbonate and its brand equivalents (Tums, Caltrate, Os-Cal), spanning 2002 through 2025. Of those, 8,716 (13.5%) listed death as an outcome and 27,035 (42.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 67% were female and 33% male; age distribution skews toward 45-64, with 13,889 reports in that bracket. The single most reported reaction is fatigue with 6,169 submissions, followed by nausea and diarrhoea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.